Society of Toxicologic Pathology Position Paper on Best Practices on Recovery Studies:The Role of the Anatomic Pathologist

Toxicologic Pathology

Volumn 41, Issue 8, 2013, Pages 1159-1169

  Perry, Rick ^a   Farris, Georgia ^b   Bienvenu, Jean Guy ^c   Dean, Charles ^d   Foley, George ^e   Mahrt, Chuck ^f   Short, Brian ^g  

^a PFIZER INC   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c CHARLES RIVER LABORATORIES   (United States)

^d AMGEN INC   (United States)

^e Lilly Research Laboratories ^*  (United States)

^f ELI LILLY AND COMPANY   (United States)

^g ALLERGAN INC   (United States)

Author keywords

best practices; ICH M3 (R2); ICH S6; ICH S9; recovery studies; reversibility

Indexed keywords

VACCINE;

ANATOMIC PATHOLOGIST; ARTICLE; CYTOPATHOLOGY; HISTOPATHOLOGY; HUMAN; INTERNATIONAL COOPERATION; MEDICAL PRACTICE; MEDICAL RESEARCH; MEDICAL SOCIETY; METHODOLOGY; NONHUMAN; PATHOLOGIST; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; TOXICITY TESTING;

BEST PRACTICES; ICH M3 (R2); ICH S6; ICH S9.; RECOVERY STUDIES; REVERSIBILITY;

ANIMALS; BIOPHARMACEUTICS; GUIDELINES AS TOPIC; PATHOLOGY; RESEARCH DESIGN; TOXICITY TESTS; TOXICOLOGY;

EID: 84887576401     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623313481513     Document Type: Article

References (44)

1. Baldrick P. (2011). Safety evaluation of biological drugs: What are toxicology studies in primates telling us? Regul Toxicol Pharmacol 59, 227–36.
2. Brennen F. R. Morton L. D. Spindeldreher S. Kiessling A. Allenspach R. Hey A. Muller P. Y. Frings W. Sims J. (2010). Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. mAbs 3, 233–55.
3. Brinks V. Jiskoot W. Schellekens H. (2011). Immunogenicity of therapeutic proteins: The use of animal models. Pharm Res 10, 2379–85.
4. Bugelski P. J. Treacy G. (2004). Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans. Curr Opin Mol Ther 6, 10–16.
5. Clarke J. Hurst C. Martin P. Vahle J. Ponce R. Mounho B. Heidel S. Andrews L. Reynolds T. Cavagnaro J. (2008). Duration of chronic toxicity studies for biotechnology-derived pharmaceuticals: Is 6 months still appropriate? Regul Toxicol Pharmacol 50, 2–22.
6. Dong J. Q. Salinger D. H. Endres C. J. Gibbs J. P. Hsu C.-P. Stouch B. J. Hurh E. Gibbs M. A. (2011). Quantitative prediction of human pharmacokinetics for monoclonal antibodies. Clin Pharmacokinet 50, 131–142.
7. EMEA (European Medicines Agency). (1997). Note for Guidance on Preclinical Pharmacological and Toxicological Testing of Vaccines. CPMP/SWP/465/95.
8. EMEA (European Medicines Agency). (1998). Note for Guidance on Pharmaceutical and Biological Aspects of Combined Vaccines. CPMP/BWP/477/98.
9. EMEA (European Medicines Agency). (2001a). Points to Consider on the Manufacture and Quality Control of Human Somatic Cell Therapy Medicinal Products. CPMP/BWP/41450/98.
10. EMEA (European Medicines Agency). (2001b). Note for Guidance on the Quality, Preclinical and Clinical Aspects of Gene Transfer Medicinal Products. CPMP/BWP/3088/99.
11. EMEA (European Medicines Agency). (2005). Guideline on Adjuvants in Vaccines for Human Use. EMEA/CHMP/VEG/134716/2004.
12. FDA (Food and Drug Administration). (2009). General biological products standards. Code of Federal Regulations, Title 21, Part 610 (21 CFR 610).
13. FDA (Food and Drug Administration, Center for Biological Evaluation and Research). (1985). Points to Consider in the Production and Testing of New Drugs and Biologicals Produced by Recombinant DNA Technology.
14. FDA (Food and Drug Administration, Center for Biological Evaluation and Research). (1998). Guidance for Industry: Guidance for Human Somatic Cell Therapy and Gene Therapy.
15. FDA (Food and Drug Administration, Center for Biological Evaluation and Research). (2005). Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers.
16. FDA (Food and Drug Administration, Center for Biological Evaluation and Research). (2006). Guidance for Industry. Considerations for Developmental Toxicity Studies for Preventive and Therapeutic Vaccines for Infectious Disease Indications.
17. FDA (Food and Drug Administration, Center for Biological Evaluation and Research). (2007) Guidance for Industry: Considerations for Plasmid DNA Vaccines for Infectious Disease Indications.
18. ICH (International Conference on Harmonisation). (2009a). ICH M3 (R2). Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. CPMP/ICH/286/95.
19. ICH (International Conference on Harmonisation). (2009b). ICH S9. Nonclinical Evaluation for Anticancer Pharmaceuticals. EMEA/CHMP/ICH/646107/2008.
20. ICH (International Conference on Harmonisation). (2011). ICH S6(R1). Preclinical Safety Evaluation of Biotechnology-derived Pharmaceuticals. EMA/CHMP/ICH/731268/1998.
21. ICH (International Conference on Harmonisation). (2012). Implementation Working Group on the M3(R2) Guideline: Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. Questions & Answers. EMA/CHMP/ICH/507008/2011.
22. Keller D. A. Juberg D. R. Catlin N. Farland W. H. Hess F. G. Wolf D. C. Doerrer N. G. (2012). Identification and characterization of adverse effects in 21st century toxicology. Toxicol Sci 126, 291–297.
23. Konigsson K. Robinson S. Harlemann H. (2010). Reduction in dog numbers in regulatory one-month toxicology studies without compromising scientific quality: Challenging the status quo. Toxicology 278, 341–378.
24. Koren E. Zuckerman L. A. Mire-Sluis A. (2002). Immunogenic responses to therapeutic proteins in humans—clinical significance, assessment and prediction. Curr Pharm Biotechnol 3, 349–360.
25. Kumar V. Abbas A. K. Fausto N. Aster J. C. (2010). Tissue renewal, regeneration, and repair. In Robbins and Cotran Pathologic Basis of Disease, 8th ed., pp. 79–110. Saunders Elsevier, Philadelphia, PA.
26. Lebron J. Wolf J. Kaplanski C. Ledwith B. (2005). Ensuring the quality, potency and safety of vaccines during preclinical development. Expert Rev Vaccines 4, 855–866.
27. Lewis R. W. Billington R. Debryune E. Gamer A. Lang B. Carpanini F. (2002). Recognition of adverse and nonadverse effects in toxicity studies. Toxicol Pathol 30, 66–74.
28. Lobo E. D. Hansen R. J. Balthasar J. P. (2004). Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93, 2645–68.
29. Lynch C. M. Hart B. W. Grewal I. S. (2009). Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies. mAbs 1, 2–11.
30. Maronpot R. Yoshizawa K. Nyska A. Harada T. Flake G. Mueller G. Singh B. Ward J., (2010). Hepatic enzyme induction: Histopathology. Toxicol Pathol 38, 776–795.
31. Olson H. Betton G. Robinson D. Thomas K. Monro A. Kolaja G. Lilly P. Sanders J. Sipes G. Bracken W. Dorato M. van Deun K. Smith P. Berger B. Heller A. (2000). Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32, 56–67.
32. Pandher K. Leach M. W. Burns-Naas L. A. (2012). Appropriate use of recovery groups in nonclinical toxicity studies: Value in a science-driven case-by-case approach. Vet Pathol 49, 357–61.
33. Ponce R. Abad L. Amaravadi L. Gelzleichter T. Gore E. Green J. Gupta S. Herzyk D. Hurst C. Ivens I. A. Kawabata T. Maier C. Mounho B. Rup B. Shankar G. Smith H. Thomas P. Wierda D. (2009). Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies. Regul Toxicol Pharmacol 54, 164–82.
34. Rosenfeldt H. Kropp T. Benson K. Stacey Ricci M. McGuinn W. D. Leigh Verbois S. (2010). Regulatory aspects of oncology drug safety evaluation: Past practice, current issues, and the challenge of new drugs. Toxicol Appl Pharmacol 243, 125–33.
35. Sparrow S. S. Robinson S. Bolam S. Bruce C. Danks A. Everett D. Fulcher S. Hill R. E. Palmer H. Scott E. W. Chapman K. L. (2011). Opportunities to minimise animal use in pharmaceutical regulatory general toxicology: A cross-company review. Regul Toxicol Pharmacol 61, 222–29.
36. Stedman’s Medical Dictionary. (2006). Stedman’s Medical Dictionary. 28th ed., pp. 1655, 1675, 1687. Lippincott Williams & Wilkins, Baltimore, MD.
37. Tabrizi M. A. Bornstein G. G. Klakamp S. L. Drake A. Knight R. Roskos L. (2009). Translational strategies for development of monoclonal antibodies from discovery to the clinic. Drug Discov Today 14, 298–305.
38. Verdier F. (2002). Non-clinical vaccine safety assessment. Toxicology 174, 37–43.
39. Verdier F. Patriarca C. Descotes J. (1997). Autoantibodies in conventional toxicity testing. Toxicology 119, 51–58.
40. Weinberg W. C. Frazier-Jessen M. R. Wu W. J. Weir A. Hartsough M. Keegan P. Fuchs C. (2005). Development and regulation of monoclonal antibody products: Challenges and opportunities. Cancer Metastasis Rev 24, 569–84.
41. WHO (World Health Organization). (2003). Guidelines on Nonclinical Evaluation of Vaccines. WHO/BS/03.1969. WHO, Geneva, Switzerland.
42. WHO (World Health Organization). (2005). Guidelines for Assuring the Quality and Nonclinical Safety Evaluation of DNA Vaccines. WHO, Geneva, Switzerland.
43. Wolf J. Kaplanski C. Lebron J. (2010). Nonclinical safety assessment of vaccines and adjuvants. In Vaccine Adjuvants: Methods and Protocols (Davies Gwyn, ed.), Vol. 626, pp. 29–40. Humana Press, New York, NY.
44. Wraith D. Goldman M. Lambert P. (2003). Vaccination and autoimmune disease: What is the evidence? Lancet 362, 1659–66.